Bafna Pharmaceuticals Ltd vs Nectar Lifescience Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 135.7 as of 30 Apr 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Nectar Lifescience Ltd changed from 21.5 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Nectar Lifescience Ltd changed from ₹ 417.13 crore on March 2021 to ₹ 515.35 crore on March 2025 . This represents a CAGR of 4.32% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Nectar Lifescience Ltd for the Dec '25 is ₹ 88.81 crore as compare to the Sep '25 revenue of ₹ 0.74 crore. This represent the growth of 11901% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Nectar Lifescience Ltd for the Dec '25 is ₹ 33.53 crore as compare to the Sep '25 ebitda of ₹ -175 crore. This represent the decline of -119% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Nectar Lifescience Ltd changed from ₹ 2.97 crore to ₹ 14.27 crore over 7 quarters. This represents a CAGR of 145.20% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Nectar Lifescience Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Nectar Lifescience Ltd

Nectar Lifescience Limited was initially incorporated on June 27, 1995 as 'Surya Medicare Limited'.
On March 26, 2004, Company changed the name from 'Surya Medicare Limited' to 'Nectar Lifescience Limited'.
NECLIFE is an integrated pharmaceutical organization, engaged in manufacturing and delivering high quality pharmaceutical products.
It is a global pharmaceutical company specializing in Cephalosporins.
Nectar excels in Cephalosporin APIs production with certified facilities meeting global standards.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Nectar Lifescience Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Nectar Lifescience Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 321 Cr while Market cap of Nectar Lifescience Ltd is 240 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Nectar Lifescience Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Nectar Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Nectar Lifescience Ltd?

As of May 3, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹135.7. On the other hand, Nectar Lifescience Ltd stock price is INR ₹12.4.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Nectar Lifescience Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Nectar Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.